GR3021875T3 - Process for preparing an activated factor VII concentrate having a high purity - Google Patents

Process for preparing an activated factor VII concentrate having a high purity

Info

Publication number: GR3021875T3
Authority: GR; Greece
Prior art keywords: factor vii; high purity; preparing; activated factor; free
Prior art date: 1991-12-16

Application number

GR960403286T

Other languages

English (en)

Inventor

Bernard Dazey

Mohamed Hamsany

Sylvia Enfedaque-Morer

Original Assignee

Aquitaine Dev Transf Sanguine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-16

Filing date

1996-12-04

Publication date

1997-03-31

1996-12-04 Application filed by Aquitaine Dev Transf Sanguine filed Critical Aquitaine Dev Transf Sanguine

1997-03-31 Publication of GR3021875T3 publication Critical patent/GR3021875T3/el

Links

108010054265 Factor VIIa Proteins 0.000 title abstract 4
239000012141 concentrate Substances 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
102100023804 Coagulation factor VII Human genes 0.000 abstract 4
108010023321 Factor VII Proteins 0.000 abstract 4
229940012413 factor vii Drugs 0.000 abstract 4
230000004913 activation Effects 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 1
101000856746 Bos taurus Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 abstract 1
229930003448 Vitamin K Natural products 0.000 abstract 1
238000004587 chromatography analysis Methods 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940012414 factor viia Drugs 0.000 abstract 1
239000003456 ion exchange resin Substances 0.000 abstract 1
229920003303 ion-exchange polymer Polymers 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract 1
238000000746 purification Methods 0.000 abstract 1
239000006228 supernatant Substances 0.000 abstract 1
235000019168 vitamin K Nutrition 0.000 abstract 1
239000011712 vitamin K Substances 0.000 abstract 1
150000003721 vitamin K derivatives Chemical class 0.000 abstract 1
229940046010 vitamin k Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

GR960403286T 1991-12-16 1996-12-04 Process for preparing an activated factor VII concentrate having a high purity GR3021875T3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9115601A FR2684999A1 (fr)	1991-12-16	1991-12-16	Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.

Publications (1)

Publication Number	Publication Date
GR3021875T3 true GR3021875T3 (en)	1997-03-31

Family

ID=9420096

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
GR930300094T GR930300094T1 (en)	1991-12-16	1993-09-30	Process for preparing an activated factor VII concentrate having a high purity
GR960403286T GR3021875T3 (en)	1991-12-16	1996-12-04	Process for preparing an activated factor VII concentrate having a high purity

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
GR930300094T GR930300094T1 (en)	1991-12-16	1993-09-30	Process for preparing an activated factor VII concentrate having a high purity

Country Status (9)

Country	Link
US (1)	US5344918A (el)
EP (1)	EP0547932B1 (el)
JP (1)	JP2533050B2 (el)
AT (1)	ATE142255T1 (el)
DE (2)	DE547932T1 (el)
DK (1)	DK0547932T3 (el)
ES (1)	ES2056782T3 (el)
FR (1)	FR2684999A1 (el)
GR (2)	GR930300094T1 (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5664362A (en) *	1993-09-03	1997-09-09	The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Fishing lure which releases the involuntary biting reflex of largemouth bass and other fishes within the family centrachidae
DE19538716A1 (de) *	1995-10-18	1997-04-24	Behringwerke Ag	Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19531637A1 (de) *	1995-08-28	1997-03-06	Immuno Ag	Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de)	1995-10-18	1997-04-30	Behringwerke Ag	Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
AU781717B2 (en) *	1998-04-24	2005-06-09	Csl Behring Gmbh	Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
AT408613B (de)	1998-06-17	2002-01-25	Immuno Ag	Pharmazeutisches faktor vii-präparat
US7049110B2 (en)	1998-07-21	2006-05-23	Gambro, Inc.	Inactivation of West Nile virus and malaria using photosensitizers
US6258577B1 (en)	1998-07-21	2001-07-10	Gambro, Inc.	Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6277337B1 (en)	1998-07-21	2001-08-21	Gambro, Inc.	Method and apparatus for inactivation of biological contaminants using photosensitizers
US7498156B2 (en)	1998-07-21	2009-03-03	Caridianbct Biotechnologies, Llc	Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6444788B1 (en) *	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
US7220747B2 (en)	1999-07-20	2007-05-22	Gambro, Inc.	Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en)	2000-06-15	2006-08-22	Gambro, Inc.	Method and apparatus for inactivation of biological contaminants using photosensitizers
DE19937218A1 (de) *	1999-08-06	2001-02-08	Aventis Behring Gmbh	Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6268120B1 (en)	1999-10-19	2001-07-31	Gambro, Inc.	Isoalloxazine derivatives to neutralize biological contaminants
US7648699B2 (en)	2000-06-02	2010-01-19	Caridianbct Biotechnologies, Llc	Preventing transfusion related complications in a recipient of a blood transfusion
TW590780B (en)	2000-06-02	2004-06-11	Gambro Inc	Additive solutions containing riboflavin
US7985588B2 (en)	2000-06-02	2011-07-26	Caridianbct Biotechnologies, Llc	Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US9044523B2 (en)	2000-06-15	2015-06-02	Terumo Bct, Inc.	Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2002351756A1 (en)	2001-12-21	2003-07-15	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
PT1517698E (pt)	2002-06-21	2014-11-19	Novo Nordisk Healthcare Ag	Composições sólidas estabilizadas de polipéptidos do fator viia
RU2364626C2 (ru)	2003-03-18	2009-08-20	Ново Нордиск Хелт Кэр Аг	Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
KR20060015574A (ko)	2003-05-23	2006-02-17	노보 노르디스크 헬스 케어 악티엔게젤샤프트	용액 중 단백질 안정화
WO2004112828A1 (en)	2003-06-25	2004-12-29	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
ES2574581T3 (es)	2003-08-14	2016-06-20	Novo Nordisk Health Care Ag	Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
EP1664108B1 (en) *	2003-08-21	2009-10-14	Novo Nordisk A/S	Separation of polypeptides comprising a racemized amino acid
RU2373953C2 (ru)	2003-12-19	2009-11-27	Ново Нордиск Хелс Кеа Аг	Стабилизированная композиция, содержащая полипептид фактора vii
EP1797180A2 (en) *	2004-09-29	2007-06-20	Novo Nordisk Health Care AG	Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
ES2257225B1 (es) *	2006-02-17	2007-03-16	Grifols, S.A	Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
FR2901707B1 (fr) *	2006-05-31	2017-09-29	Lab Francais Du Fractionnement	Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) *	2006-08-01	2008-10-17	Lab Francais Du Fractionnement	"composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2917414B1 (fr) *	2007-06-15	2012-07-13	Lab Francais Du Fractionnement	Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci
FR2942231B1 (fr)	2009-02-19	2015-03-20	Lfb Biotechnologies	Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
CA2821711C (en)	2010-12-15	2017-10-10	Baxter International Inc.	Eluate collection using conductivity gradient
EP2687595B1 (en)	2012-07-19	2018-05-30	Laboratoire Français du Fractionnement et des Biotechnologies	Method for purifying transgenic factor VII

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5314604B2 (el) *	1972-12-20	1978-05-18
JPS57206620A (en) *	1981-06-12	1982-12-18	Cutter Lab	Blood coagulation promoter and manufacture
US4540473A (en) *	1983-11-22	1985-09-10	International Business Machines Corporation	Copper plating bath having increased plating rate, and method
US4473553A (en) *	1983-12-02	1984-09-25	Miles Laboratories, Inc.	Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa
US4470969A (en) *	1983-12-02	1984-09-11	Miles Laboratories, Inc.	Process for producing a concentrate of coagulation factors VII and VIIa
FR2632524B1 (fr) *	1988-06-09	1992-03-13	Fondation Nale Transfusion San	Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament

1991
- 1991-12-16 FR FR9115601A patent/FR2684999A1/fr active Granted
1992
- 1992-12-01 ES ES92403234T patent/ES2056782T3/es not_active Expired - Lifetime
- 1992-12-01 DE DE92403234T patent/DE547932T1/de active Pending
- 1992-12-01 EP EP92403234A patent/EP0547932B1/fr not_active Expired - Lifetime
- 1992-12-01 DE DE69213421T patent/DE69213421T2/de not_active Expired - Lifetime
- 1992-12-01 AT AT92403234T patent/ATE142255T1/de active
- 1992-12-01 DK DK92403234.5T patent/DK0547932T3/da active
- 1992-12-10 US US07/988,776 patent/US5344918A/en not_active Expired - Lifetime
- 1992-12-16 JP JP4354440A patent/JP2533050B2/ja not_active Expired - Fee Related
1993
- 1993-09-30 GR GR930300094T patent/GR930300094T1/el unknown
1996
- 1996-12-04 GR GR960403286T patent/GR3021875T3/el unknown

Also Published As

Publication number	Publication date
DK0547932T3 (da)	1997-02-10
ATE142255T1 (de)	1996-09-15
DE69213421T2 (de)	1997-04-03
FR2684999A1 (fr)	1993-06-18
JPH05345799A (ja)	1993-12-27
EP0547932A1 (fr)	1993-06-23
JP2533050B2 (ja)	1996-09-11
ES2056782T1 (es)	1994-10-16
ES2056782T3 (es)	1997-02-16
GR930300094T1 (en)	1993-09-30
DE69213421D1 (de)	1996-10-10
FR2684999B1 (el)	1995-05-05
US5344918A (en)	1994-09-06
EP0547932B1 (fr)	1996-09-04
DE547932T1 (de)	1994-02-03

Publication	Publication Date	Title
FR2684999B1 (el)	1995-05-05
US5565427C1 (en)	2002-07-23	Stabilized factor viii preparations
BG102733A (en)	1999-04-30	New substituted cyclic amino acids as pharmaceutical forms
EP0723555A4 (en)	1999-04-28	CHEMICAL PROTEINS WITH BLOCK SUPPLEMENT ACTIVATION
CA1267496C (en)	1990-04-03	PURIFICATION AND ACTIVATION OF INSOLUBLE INCLUSION BODY PROTEINS
WO1990014067A3 (en)	1991-04-04	Methods for treating anxiety with sigma receptor ligands
MY109990A (en)	1997-10-31	Microfluidised particles of atovaquone and pharmaceutical preparation thereof
AU2724492A (en)	1993-04-29	Antibodies in immunosuppression
NZ330837A (en)	1999-03-29	Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon
DE3687007D1 (en)	1992-12-03	6-thioxanthinderivate.
EP0233013A3 (en)	1987-10-14	Modified enzyme
AU580348B2 (en)	1989-01-12	A process for the cleavage of peptides and proteins at the methionyl bond
DE3571201D1 (en)	1989-08-03	Process for producing a high purity antihemophilic factor concentrate
ES8302017A1 (es)	1983-01-01	Procedimiento para la preparacion de un alto concentrado de factor viii (ahf).
AU3687593A (en)	1993-10-28	A method of producing a factor VIII preparation
EP1199361A3 (en)	2004-03-10	Glycoprotein hormone receptor molecules. Their uses
AU2850292A (en)	1993-05-20	A process for the production of a virus-free concentrate of thrombin
EP0373540A3 (en)	1991-10-02	Method for purifying fibroblast growth factor protein
JPS6456699A (en)	1989-03-03	Method for obtaining alpha 1-antitrypsin concentrate from human plasma and its utilization as drug
IL111925A (en)	2000-06-01	Preparation of agents containing virus-inactivated vitamin K-dependent plasma components protein C and protein S by membrane chromatography
AU8003294A (en)	1995-05-22	Human activated protein c preparation and process for producing the same
MX9702341A (es)	1997-06-28	Citoquina designada lerk-6.
MY119366A (en)	2005-05-31	A process for the preparation of factor ix from biological sources
DK0378432T3 (da)	1995-05-01	Peptider, deres anvendelse til inhibering af modningen af T-lymfocytter og aktiviteten af makrofager samt fremgangsmåder til deres fremstilling
HUT53125A (en)	1990-09-28	Process for producing peptides with anticoagulant activity